| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| Neuraminidase (NA) | Influenza A virus (Missouri/11/2025) NA (H1N1) Protein, His Tag | Influenza A virus (Missouri/11/2025) | HEK293 | ![]() | SDS-PAGE | $350.00 100ug | ||
| Neuraminidase (NA) | Influenza A virus (Sydney/1359/2024)& (Singapore/GP20238/2024) NA (H3N2) Protein, His Tag | Influenza A virus (Sydney/1359/2024)& (Singapore/GP20238/2024) | HEK293 | ![]() | SDS-PAGE | $350.00 100ug | ||
| Neuraminidase (NA) | Influenza A virus (A/Croatia/10136RV/2023) & (A/District of Columbia/27/2023) NA(H3N2) Protein, His Tag | Influenza A virus (A/Croatia/10136RV/2023) & (A/District of Columbia/27/2023) | HEK293 | SDS-PAGE | $360.00 100ug | |||
| Neuraminidase (NA) | Avitag NEE-V82Q3 | Biotinylated Influenza A virus (A/Victoria/4897/2022) NA (H1N1) Protein, Avitag™,His Tag | Influenza A virus (A/Victoria/4897/2022) | HEK293 | ![]() | SDS-PAGE | $380.00 25ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| CD388 | CD-388; JNJ-0953; CD388 | Phase 3 Clinical | Cidara Therapeutics Inc | Influenza, Human | Details |
| Peramivir Inhalation Solution (Langtian Medical Tech) | Phase 2 Clinical | Langtian Medical Technology (Wuhan) Co Ltd | Influenza A virus infections; Influenza B virus infection | Details | |
| Peramivir Inhalation Solution (广州南鑫药业) | Phase 2 Clinical | Guangzhou Nanxin Pharma Co Ltd | Arthralgia; Cough; Fatigue; Headache; Influenza A virus infections; Influenza B virus infection; Influenza, Human; Musculoskeletal Pain; Nasal Obstruction | Details | |
| Oseltamivir/Pimodivir | Phase 1 Clinical | Johnson & Johnson | Influenza A virus infections | Details | |
| Oseltamivir orally disintegrating tablets(Hefei Industrial Pharma) | HY-100209 | Phase 1 Clinical | Hefei Industrial Pharmaceutical Co Ltd | Influenza A virus infections; Influenza B virus infection | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Laninamivir Octanoate Hydrate | CS-8958; R-118958 | Approved | Daiichi Sankyo Co Ltd | Inavir | Japan | Influenza B virus infection; Influenza A virus infections; Influenza, Human | null | 2010-09-10 | Asthma; Influenza A virus infections; Influenza B virus infection; Influenza, Human | Details |
| Zanamivir | GG-167; GR-121167; GR-121167X; 4-Guanidino-Neu5Ac2en | Approved | Glaxosmithkline Plc | 依乐韦, Relenza | United States | Influenza, Human | Glaxosmithkline Plc | 1999-07-26 | Arthralgia; Dengue; Diabetes Mellitus, Type 2; Influenza, Human; Orthomyxoviridae Infections | Details |
| Oseltamivir Phosphate | Ro-64-0796; RO-640796; GS-4104; EN-241104; RO-640796/002; GS-4104/002; GS-4104-002 | Approved | F. Hoffmann-La Roche Ltd, Gilead Sciences Inc | Tamiflu, Hanmi Flu, 达菲 | Switzerland | Influenza, Human | F. Hoffmann-La Roche Ltd | 1999-09-21 | Influenza A virus infections; Influenza in Birds; Influenza, Human; Kidney Failure, Chronic; Obesity; Purpura, Thrombocytopenic, Idiopathic | Details |
| Peramivir Hydrate | BCX-1812; JNJ-2; S-021812; RWJ-270201 | Approved | Biocryst Pharmaceuticals Inc | Peramiflu, Alpivab, 力纬, Rapiacta, Rapivab, Enpiflu Premix | Japan | Influenza, Human | null | 2010-01-13 | Cough; Fatigue; Fever; Headache; Influenza A virus infections; Influenza B virus infection; Influenza, Human; Myalgia; Nasal Obstruction; Pharyngitis | Details |